Company: ANTX
Filing Date: 2025-04-10
Form Type: DEFA14A
Source: 0000950170-25-052853
Chunk: 1

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-04-10
Form: DEFA14A
Chunk 1
---
 time for this year's meeting, you must make this request on or before May 12, 2025. SEE REVERSE FOR FULL AGENDA Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to be Held on May 22, 2025 for Stockholders of Record as of March 24, 2025 To order paper materials, use one of the following methods. Internet:www.investorelections.com/ANTXCall: 1-866-648-8133 Email:paper@investorelections.com* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved

AN2 Therapeutics AN2 Therapeutics, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: "FOR" each of the nominees in Proposal 1 and "FOR" Proposal 2 PROPOSAL 1. To elect each of the following nominees as Class III directors until the 2028 annual meeting of stockholders or until their respective successors have been elected or appointed. 1.01 Eric Easom 1.02 Stephanie Wong 1.03 Joseph Zakrzewski 2. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. NOTE: In their discretion, the Named Proxies are authorized to vote upon such other business properly brought before the Annual Meeting or any adjournments or postponements thereof.